Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
Dhainaut
Jean-François
JF
Medical Intensive Care Unit, Cornil Building, Cochin Port-Royal University Hospital, 27 rue de Faubourg Saint Jacques, F75679 Paris Cedex 14, France. dhainaut@cochin.univ-paris5.fr
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D018836:Inflammation Mediators / Q000502:physiology; D011486:Protein C / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology*
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005343:Fibrinolytic Agents; D018836:Inflammation Mediators; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated